Sarepta Therapeutics, Inc.
SRPT · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $2.20B | $1.90B | +15.6% |
| Operating income | −$700M | $218M | |
| Net income | −$713M | $235M |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $381M | $399M | −4.5% |
| Operating income | −$9.00M | −$103M | +91.3% |
| Net income | −$28.5M | −$50.6M | +43.7% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Sarepta's revenue in FY2025?
- $2.20B in FY2025 (Fiscal year ended Dec 31, 2025), +15.6% vs $1.90B a year earlier, per its 10-K filed Mar 2026.
- Was Sarepta profitable in FY2025?
- No: net income was −$713M and operating income −$700M in FY2025.
- What was Sarepta's revenue in Q3 2026?
- $381M (−4.5% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.